DENVER, Aug. 4, 2014 /PRNewswire/ -- MusclePharm
Corporation (OTCQB: MSLP), a scientifically driven,
performance-lifestyle sports nutrition company, is proud to
announce it has signed a multi-year endorsement deal with former
Heisman Trophy winner and NFL first-round draft pick Johnny Manziel.
Manziel, who is also known by his nickname "Johnny Football,"
was drafted by the Cleveland Browns with the 22nd pick
in the first round of the 2014 NFL Draft. In 2012, the Texas
A&M Aggies first season in the SEC, Manziel debuted for the
team as a redshirt freshman. He broke numerous NCAA Division I FBS
as well as SEC records, including becoming the first freshman and
only the fifth player in NCAA history to pass for 3000 yards and
rush for 1000 yards in a single season. At the end of
the regular season, he became the first freshman to win the Heisman
Trophy, as well as the Manning Award and the Davey O'Brien National
Quarterback Award.
"I'm proud to join a lineup of competitive athletes from around
the world who know MusclePharm as the top sports nutrition
innovator and industry leader," said Manziel. "Top athletes
know that MusclePharm has what they need to perform at their very
best."
In addition to Manziel, MusclePharm's stable of endorsers
includes Tiger Woods, Arnold
Schwarzenegger, and professional football players
Eric Decker and Colin Kaepernick. MusclePharm is also the
Official Supplement Provider of Ultimate Fighting Championship®
(UFC) and USA Wrestling.
Commenting on the announcement, MusclePharm Founder & CEO,
Brad Pyatt, stated, "Manziel is an
electrifying athlete and a proven winner with a rare and dynamic
athleticism. His work ethic combined with his relentless
competitive drive make him an ideal fit for the MusclePharm brand.
We are excited for the future."
About MusclePharm
MusclePharm® is a scientifically driven, performance-lifestyle
company that currently develops, manufactures, markets and
distributes branded nutritional supplements. The company offers a
complete range of powders, capsules, tablets and gels. Its
portfolio of recognized brands, including MusclePharm® Hybrid and
Core Series, Arnold Schwarzenegger Series™ and FitMiss®, are
marketed and sold in more than 110 countries and available in over
35,000 retail outlets globally. These clinically-proven and
scientific nutritional supplements are developed through a
six-stage research process utilizing the expertise of leading
nutritional scientists, doctors and universities. MusclePharm is
the innovator of the sports nutrition industry. For more
information, visit www.musclepharm.com.
Forward-Looking Statements
This
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities and Exchange Act of 1934, as amended.
Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects",
"anticipates", "intends", "estimates", "plans", "potential",
"possible", "probable", "believes", "seeks", "may", "will",
"should", "could" or the negative of such terms or other similar
expressions. Actual results may differ materially from those set
forth in this release due to the risks and uncertainties inherent
in the Company's business. More detailed information about the
Company and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company's Annual
Report on Form 10-K for the fiscal year ended December 31, 2012, the Company's Quarter Reports
on Form 10-Q and other filings submitted by the Company to the SEC,
copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement and the Company undertakes no
obligation to revise or update this release to reflect events or
circumstances after the date hereof.
Photo - http://photos.prnewswire.com/prnh/20140804/132838
SOURCE MusclePharm Corporation